IMR Press / FBL / Volume 14 / Issue 10 / DOI: 10.2741/3504

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Tumor angiogenesis and molecular targets for therapy

Show Less
1 Laboratory of Angiogenesis Research, Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 171 77 Stockholm, Sweden

Academic Editor: Rolf Bjerkvig

Front. Biosci. (Landmark Ed) 2009, 14(10), 3962–3973;
Published: 1 January 2009
(This article belongs to the Special Issue Tumor angiogenesis and molecular targets)

Tumors produce multiple angiogenic factors to induce neovascularization by angiogenesis, vasculogenesis and vascular remodeling. Although tumors utilize similar mechanisms as normal growing tissues, tumor blood vessels usually appear as malformed vasculatures that have several distinctive features including a high degree of disorganization, lack of clear separation between arterioles and venules, lack of appropriate coating with mural cells, high permeability, and composition of mosaic cell types, which might express specific markers. These unusual features of tumor blood vessels offer a great opportunity for therapeutic intervention and might paradoxically restrict cytotoxic drug delivery. Following an initial clinical success of bevacizumab in combination with chemotherapy for the treatment of human colorectal cancer, several other anti-angiogenesis agents are now available in the clinic. Understanding basic mechanisms of tumor angiogenesis, defining novel and accurate molecular targets, designing optimal clinical trials, and minimizing side effects are crucial issues for a further successful development of anti-angiogenic compounds for the treatment of various human cancers.

Back to top